Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2012 | Research

MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells

Authors: Chen Wang, Xiangqian Zheng, Chunyan Shen, Yurong Shi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Abstract

Background

This study was performed to investigate the effect of microRNA-203 (miR-203) on cell proliferation and migration in triple-negative breast cancer (TNBC).

Methods

Real-time PCR was performed to detect the expression of miR-203 in TNBC cell lines. miR-203 precursor and control microRNA (miRNA) were transfected into triple-negative breast cancer (TNBC) cell lines and the effects of miR-203 up-regulation on the proliferation and migration of cells were investigated. Meanwhile, the mRNA and protein levels of baculoviral IAP repeat-containing protein 5 (BIRC5) and Lim and SH3 domain protein 1 (LASP1) were measured. Luciferase assays were also performed to validate BIRC5 and LASP1 as miR-203 targets.

Results

Both miR-203 and BIRC5 siRNA signicantly inhibited cell proliferation in TNBC cells. Both miR-203 and LASP1 siRNA signicantly inhibited cell migration in TNBC cells, also. Moreover, up-regulated of BIRC5 and LASP1 was able to abrogate the effects induced by transfection with the miR-203 precursor.

Conclusions

These data suggest that miR-203 may function as a tumor suppressor in TNBC cells. Thus, miR-203 could be a potential therapeutic target for this disease.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed

Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W: Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005, 309: 1573-1576. 10.1126/science.1115079.CrossRefPubMed

Pillai RS: MicroRNA function: multiple mechanisms for a tiny RNA?. RNA. 2005, 11: 1753-1761. 10.1261/rna.2248605.PubMedCentralCrossRefPubMed

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci. 2004, 101: 2999-3004. 10.1073/pnas.0307323101.PubMedCentralCrossRefPubMed

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838. 10.1038/nature03702.CrossRefPubMed

Engels BM, Hutvagner G: Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 2006, 25: 6163-6169. 10.1038/sj.onc.1209909.CrossRefPubMed

Bartel DP, Chen CZ: Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004, 5: 396-400.CrossRefPubMed

Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, Aboukameel A, Padhye S, Philip PA, Sarkar FH: Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One. 2011, 6: e17850-10.1371/journal.pone.0017850.PubMedCentralCrossRefPubMed

Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, Kreipe H, Schlegelberger B, Beger C: MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer. 2011, 129: 2797-2806. 10.1002/ijc.25962.CrossRefPubMed

10.

Bueno MJ, Pérez De Castro I, Gómez De Cedrón M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernández-Piqueras J, Malumbres M: Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008, 13: 496-506. 10.1016/j.ccr.2008.04.018.CrossRefPubMed

11.

Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010, 31: 766-776. 10.1093/carcin/bgp250.CrossRefPubMed

12.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008, 299: 425-436. 10.1001/jama.299.4.425.PubMedCentralPubMed

13.

Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermüller J: MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2012, : -10.1038/onc.2012.55.PubMed

14.

Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, Zhang J, Zhao J, Yang AG, Zhang R: MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett. 2012, 586: 804-809. 10.1016/j.febslet.2012.01.050.CrossRefPubMed

15.

Hummel R, Hussey DJ, Haier J: MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010, 46: 298-311. 10.1016/j.ejca.2009.10.027.CrossRefPubMed

16.

Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010, 9: 775-789. 10.1038/nrd3179.PubMedCentralCrossRefPubMed

17.

Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, Huang SD: MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer. 2011, 11: 57-10.1186/1471-2407-11-57.PubMedCentralCrossRefPubMed

18.

Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3: 917-921. 10.1038/nm0897-917.CrossRefPubMed

19.

Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Taniga-wa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000, 6: 127-134.PubMed

20.

Dubrez-Daloz L, Dupoux A, Cartier J: IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle. 2008, 7: 1036-1046. 10.4161/cc.7.8.5783.CrossRefPubMed

21.

Altieri DC: The case for survivin as a regulator of microtubule dynamics and cell death decisions. Curr Opin Cell Biol. 2006, 18: 609-615. 10.1016/j.ceb.2006.08.015.CrossRefPubMed

22.

Hinnis A, Luckett J, Walker R: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 2007, 96: 639-645. 10.1038/sj.bjc.6603616.PubMedCentralCrossRefPubMed

23.

Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B: Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin Breast Cancer. 2011, 11: 129-134. 10.1016/j.clbc.2011.03.002.CrossRefPubMed

24.

Izawa A, Kobayashi D, Nasu S, Saito K, Moriai R, Asanuma K, Nakamura M, Yagihashi A, Watanabe N: Relevance of c-erbB-2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer. Anticancer Res. 2002, 22: 2965-2969.PubMed

25.

Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer. 2003, 88: 1077-1083. 10.1038/sj.bjc.6600776.PubMedCentralCrossRefPubMed

26.

Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer. 2006, 107: 746-756. 10.1002/cncr.22044.CrossRefPubMed

27.

Grunewald TG, Butt E: The LIM and SH3 domain protein family: structural proteins or signal transducers or both?. Mol Cancer. 2008, 7: 31-10.1186/1476-4598-7-31.PubMedCentralCrossRefPubMed

28.

Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M, Butt E: Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res. 2006, 312: 974-982. 10.1016/j.yexcr.2005.12.016.CrossRefPubMed

29.

Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, Butt E: Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localization. Br J Cancer. 2007, 96: 296-305. 10.1038/sj.bjc.6603545.PubMedCentralCrossRefPubMed

30.

Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott PA, Witt H, Ryzhova M, Felsberg J, Benner A, Riester S, Scheurlen W, Grunewald TG, von Deimling A, Kulozik AE, Reifenberger G, Taylor MD, Lichter P, Butt E, Pfister SM: Role of LIM and SH3 Protein 1 (LASP1) in the metastastic dissemination of medulloblastoma. Cancer Res. 2010, 70: 8003-8014. 10.1158/0008-5472.CAN-10-0592.CrossRefPubMed

Title: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells
Authors: Chen Wang
Xiangqian Zheng
Chunyan Shen
Yurong Shi
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-31-58

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma

The cost of unresectable stage III or stage IV melanoma in Italy

Elevated expression of chloride intracellular channel 1 is correlated with poor prognosis in human gliomas

TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model

Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer